Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model.
Pia GattingerBernhard KratzerAl Nasar Ahmed SehgalAnna Ohradanova-RepicLaura GebetsbergerGabor TajtiMargarete Focke-TejklMirjam SchaarVerena FuhrmannLukas PetrowitschWalter KellerSandra HöglerHannes StockingerWinfried F PicklRudolf ValentaPublished in: Vaccines (2024)
Among the tested immunogens, the chimeric PreS-RBD subunit vaccine, W-PreS-O, induced the highest neutralizing antibody titers against Omicron. Thus, W-PreS-O seems to be a highly promising COVID-19 vaccine candidate for further preclinical and clinical evaluation.